deucravacitinib,vedolizumab,zasocitinib,apremilast
takeda,bms,amgen
['psoriasis', '$bmy', 'takeda', '$tak']
at #aad2023, presented the phase 2 data that convinced it to pay $4b to acquire a drug with best-in-class potential in #psoriasis and other autoimmune indications. story via . $tak $bmy 
Tracking what's next in medical innovation from hospitals, payers, medtech, pharma, digital & beyond. A @breakingmedia site.